Mast cell chymase affects the functional properties of primary human airway fibroblasts: Implications for asthma - 03/02/22
Abstract |
Background |
Mast cells (MCs) have a profound impact on allergic asthma. Under such conditions, MCs undergo degranulation, resulting in the release of exceptionally large amounts of MC-restricted proteases. However, the role of these proteases in asthma is only partially understood.
Objectives |
We sought to test our hypothesis that MC proteases can influence the functionality of human lung fibroblasts (HLFs).
Methods |
Primary HLFs were treated with MC chymase or tryptase, followed by assessment of parameters related to fibroblast function.
Results |
HLFs underwent major morphologic changes in response to chymase, showing signs of cellular contraction, but were refractory to tryptase. However, no effects of chymase on HLF viability or proliferation were seen. Chymase, but not tryptase, had a major impact on the output of extracellular matrix–associated compounds from the HLFs, including degradation of fibronectin and collagen-1, and activation of pro–matrix metalloprotease 2. Further, chymase induced the release of various chemotactic factors from HLFs. In line with this, conditioned medium from chymase-treated HLFs showed chemotactic activity on neutrophils. Transcriptome analysis revealed that chymase induced a proinflammatory gene transcription profile in HLFs, whereas tryptase had minimal effects.
Conclusions |
Chymase, but not tryptase, has a major impact on the phenotype of primary airway fibroblasts by modifying their output of extracellular matrix components and by inducing a proinflammatory phenotype.
Le texte complet de cet article est disponible en PDF.Key words : Mast cells, chymase, tryptase, fibroblasts, asthma
Abbreviations used : CPA3, CXCL, ECM, EdU, ELISA, HGF, HLF, IGFBP, MC, MMP, SMC, uPAR
Plan
Supported by grants from the Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Cancer Foundation, and the Knut & Alice Wallenberg Foundation. |
|
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 149 - N° 2
P. 718-727 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?